Incidence, prevalence, and trends in polycystic ovary syndrome diagnosis: a United States population-based study from 2006 to 2019
- PMID: 37061077
- DOI: 10.1016/j.ajog.2023.04.010
Incidence, prevalence, and trends in polycystic ovary syndrome diagnosis: a United States population-based study from 2006 to 2019
Abstract
Background: Polycystic ovary syndrome is the most common endocrine disorder in women of reproductive age, yet US incidence estimates do not exist, and prevalence estimates vary widely.
Objective: A population-based US study estimated the incidence, prevalence, and trends of polycystic ovary syndrome by age, race and ethnicity, and diagnosing provider type.
Study design: A retrospective cohort study of patients enrolled in Kaiser Permanente Washington from 2006 to 2019 was conducted. All members identified as female, aged 16 to 40 years with at least 3 years of enrollment and at least 1 healthcare encounter during that time, were eligible for inclusion. Individuals were excluded if they had a history of oophorectomy or hysterectomy. Polycystic ovary syndrome cases were identified using the International Classification of Diseases diagnosis codes (International Classification of Diseases, Ninth Revision, 256.4 or International Classification of Diseases, Tenth Revision, E28.2). Individuals with a polycystic ovary syndrome diagnosis before study entry were excluded from incidence rate estimations. The incidence rates were adjusted by age using direct standardization to the 2010 US census data. Temporal trends in incidence were assessed using weighted linear regression (overall) and Poisson regression (by age, race and ethnicity, and provider type). Prevalent cases were defined as patients with a polycystic ovary syndrome diagnosis at any time before the end of 2019. Medical record review of 700 incident cases diagnosed in 2011-2019 was performed to validate incident cases identified by International Classification of Diseases codes using the Rotterdam criteria.
Results: Among 177,527 eligible patients who contributed 586,470 person-years, 2491 incident polycystic ovary syndrome cases were identified. The mean age at diagnosis was 26.9 years, and the mean body mass index was 31.6 kg/m2. Overall incidence was 42.5 per 10,000 person-years; the rates were similar over time but increased in individuals aged 16 to 20 years from 31.0 to 51.9 per 10,000 person-years (P=.01) and decreased among those aged 26 to 30 years from 82.8 to 45.0 per 10,000 person-years (P=.02). A small decreasing temporal trend in incidence rates was only observed among non-Hispanic White individuals (P=.01). The incidence rates by diagnosing provider type varied little over time. Among the 58,241 patients who contributed person-time in 2019, 3036 (5.2%) had a polycystic ovary syndrome International Classification of Diseases diagnosis code; the prevalence was the highest among the Hawaiian and Pacific Islander group (7.6%) followed by Native American and Hispanic groups. Medical record review classified 60% as definite or probable incident, 14% as possible incident, and 17% as prevalent polycystic ovary syndrome. The overall positive predictive value of polycystic ovary syndrome International Classification of Diseases diagnosis code for identifying definite, probable, or possible incident polycystic ovary syndrome was 76% (95% confidence interval, 72%-79%).
Conclusion: Among a cohort of nonselected females in the United States, we observed stable rates of incident polycystic ovary syndrome diagnoses over time. The incidence of polycystic ovary syndrome was 4- to 5-fold greater than reported for the United Kingdom. The prevalence of polycystic ovary syndrome (5.2%) was almost double before the published US estimates (2.9%) based on the International Classification of Diseases codes. Race and ethnicity and provider type did not seem to have a major impact on temporal rates. Incident diagnoses increased over time in younger and decreased in older age groups, perhaps related to shifting practice patterns with greater awareness among practitioners of the impact of polycystic ovary syndrome on long-term health outcomes and improved prevention efforts. Moreover, increasing obesity rates may be a factor driving the earlier ages at diagnosis.
Keywords: age; incidence; polycystic ovary syndrome; prevalence; provider type; race; temporal trends.
Copyright © 2023 Elsevier Inc. All rights reserved.
Similar articles
-
Incidence, prevalence, and trends in endometriosis diagnosis: a United States population-based study from 2006 to 2015.Am J Obstet Gynecol. 2021 Nov;225(5):500.e1-500.e9. doi: 10.1016/j.ajog.2021.06.067. Epub 2021 Jun 17. Am J Obstet Gynecol. 2021. PMID: 34147493
-
Adenomyosis incidence, prevalence and treatment: United States population-based study 2006-2015.Am J Obstet Gynecol. 2020 Jul;223(1):94.e1-94.e10. doi: 10.1016/j.ajog.2020.01.016. Epub 2020 Jan 15. Am J Obstet Gynecol. 2020. PMID: 31954156
-
A US population-based study of uterine fibroid diagnosis incidence, trends, and prevalence: 2005 through 2014.Am J Obstet Gynecol. 2018 Dec;219(6):591.e1-591.e8. doi: 10.1016/j.ajog.2018.09.039. Epub 2018 Oct 3. Am J Obstet Gynecol. 2018. PMID: 30291840
-
Direct economic burden of mental health disorders associated with polycystic ovary syndrome: Systematic review and meta-analysis.Elife. 2023 Aug 3;12:e85338. doi: 10.7554/eLife.85338. Elife. 2023. PMID: 37534878 Free PMC article.
-
Health Care-Related Economic Burden of Polycystic Ovary Syndrome in the United States: Pregnancy-Related and Long-Term Health Consequences.J Clin Endocrinol Metab. 2022 Jan 18;107(2):575-585. doi: 10.1210/clinem/dgab613. J Clin Endocrinol Metab. 2022. PMID: 34546364
Cited by
-
Global burden of polycystic ovary syndrome among women of childbearing age, 1990-2021: a systematic analysis using the global burden of disease study 2021.Front Public Health. 2025 Mar 26;13:1514250. doi: 10.3389/fpubh.2025.1514250. eCollection 2025. Front Public Health. 2025. PMID: 40206176 Free PMC article.
-
Association of Polycystic Ovarian Syndrome Features and Metabolic Syndrome Among Reproductive-Aged Women in the United States.Womens Health Rep (New Rochelle). 2025 Apr 14;6(1):431-441. doi: 10.1089/whr.2024.0143. eCollection 2025. Womens Health Rep (New Rochelle). 2025. PMID: 40308359 Free PMC article.
-
Prevalence of subclinical hypothyroidism in polycystic ovary syndrome and its impact on insulin resistance: a systematic review and meta-analysis.BMC Endocr Disord. 2025 Mar 19;25(1):75. doi: 10.1186/s12902-025-01896-2. BMC Endocr Disord. 2025. PMID: 40102852 Free PMC article.
-
The Acari Hypothesis, VII: accounting for the comorbidity of allergy with other contemporary medical conditions, especially metabolic syndrome.Front Allergy. 2025 Mar 27;6:1537467. doi: 10.3389/falgy.2025.1537467. eCollection 2025. Front Allergy. 2025. PMID: 40212291 Free PMC article.
-
Thyroid Disorders in Patients with Polycystic Ovarian Syndrome in a Tertiary Care Center: An Observational study.JNMA J Nepal Med Assoc. 2024 Dec;62(280):819-822. doi: 10.31729/jnma.8833. Epub 2024 Dec 31. JNMA J Nepal Med Assoc. 2024. PMID: 40654392 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical